Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
Posted inHematology-Oncology news Oncology

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1-positive advanced triple-negative breast cancer.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
Posted innews Oncology

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminating the need for cyclophosphamide pretreatment.
Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
Posted innews Oncology

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated in premenopausal women; hematologic toxicity increased.